Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Novavax Inc (NASDAQ:NVAX)

1.24
Delayed Data
As of Dec 02
 +0.06 / +5.08%
Today’s Change
1.16
Today|||52-Week Range
9.23
-85.22%
Year-to-Date
The Worst Biotech Stocks of 2016
Dec 02 / MotleyFool.com - Paid Partner Content
A Strong Case for Selling Novavax, Inc. Stock
Nov 22 / MotleyFool.com - Paid Partner Content
3 Drug Stocks Investors Shouldn't Touch With a 10-Foot Pole in 2017
Dec 01 / MotleyFool.com - Paid Partner Content
Penny Stocks: 2 to Buy, 2 to Avoid
Nov 20 / MotleyFool.com - Paid Partner Content

Today’s Trading

Previous close1.18
Today’s open1.18
Day’s range1.17 - 1.26
Volume4,794,798
Average volume (3 months)15,304,802
Market cap$320.1M
Dividend yield--
Data as of 4:00pm ET, 12/02/2016

Growth & Valuation

Earnings growth (last year)-62.16%
Earnings growth (this year)-75.05%
Earnings growth (next 5 years)0.00%
Revenue growth (last year)+18.24%
P/E ratioNM
Price/Sales60.70
Price/Book1.09

Competitors

 Today’s
change
Today’s
% change
GERNGeron Corp+0.05+2.55%
SYRSSyros Pharmaceutical...+1.39+9.87%
EDGEEdge Therapeutics In...-0.07-0.61%
BTXBioTime Inc-0.06-1.85%
Data as of 4:00pm ET, 12/02/2016

Financials

Next reporting dateMarch 13, 2017
EPS forecast (this quarter)-$0.23
Annual revenue (last year)$36.3M
Annual profit (last year)-$156.9M
Net profit margin-432.93%

Profile

Sector
Health Technology
Industry
Biotechnology
President, Chief Executive Officer &
Director
Stanley C. Erck
Senior Vice President-
Quality Operations
Robert Darius
Corporate headquarters
Gaithersburg, Maryland

Forecasts


Search for Jobs